1.
Barlogie
B,
Mitchell
A, van
Rhee
F, et al.
Curing myeloma at last: defining criteria and providing the
evidence . Blood.
2014; ; 124:
:3043.–3051.
2.
van de
Donk
NW,
Moreau
P,
Plesner
T, et al.
Clinical efficacy and management of monoclonal antibodies
targeting CD38 and SLAMF7 in multiple myeloma .
Blood.
2016; ; 127:
:681.–695.
3.
van de
Donk
N,
Richardson
PG,
Malavasi
F. CD38 antibodies
in multiple myeloma: back to the future .
Blood.
2018; ; 131:
:13.–29.
4.
Munoz
P,
Mittelbrunn
M, de la
Fuente
H, et al.
Antigen-induced clustering of surface CD38 and recruitment of
intracellular CD38 to the immunologic synapse .
Blood.
2008; ; 111:
:3653.–3664.
5.
Howard
M,
Grimaldi
JC,
Bazan
JF, et al.
Formation and hydrolysis of cyclic ADP-ribose catalyzed by
lymphocyte antigen CD38 .
Science.
1993; ; 262:
:1056.–1059.
6.
van de
Donk
N,
Usmani
SZ. CD38 Antibodies
in multiple myeloma: Mechanisms of action and modes of
resistance . Front Immunol.
2018; ; 9: :2134..
7.
van de
Donk
NW,
Janmaat
ML,
Mutis
T, et al.
Monoclonal antibodies targeting CD38 in hematological
malignancies and beyond . Immunol
Rev.
2016; ; 270:
:95.–112.
8.
de Weers
M,
Tai
YT, van der
Veer
MS, et al.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody,
induces killing of multiple myeloma and other hematological
tumors . J Immunol.
2011; ; 186:
:1840.–1848.
9.
Deckert
J,
Wetzel
MC,
Bartle
LM, et al.
SAR650984, a novel humanized CD38-targeting antibody,
demonstrates potent antitumor activity in models of multiple myeloma and
other CD38+ hematologic malignancies . Clin
Cancer Res.
2014; ; 20:
:4574.–4583.
10.
Lammerts van
Bueren
J,
Jakobs
D,
Kaldenhoven
N, et al.
Direct in vitro comparison of daratumumab with surrogate analogs
of CD38 antibodies MOR03087, SAR650984 and Ab79 .
Blood.
2014;; 124: :3474.-.
11.
Jiang
H,
Acharya
C,
An
G, et al.
SAR650984 directly induces multiple myeloma cell death via
lysosomal-associated and apoptotic pathways, which is further enhanced by
pomalidomide . Leukemia.
2016; ; 30:
:399.–408.
12.
Krejcik
J,
Casneuf
T,
Nijhof
IS, et al.
Daratumumab depletes CD38+ immune regulatory cells, promotes
T-cell expansion, and skews T-cell repertoire in multiple
myeloma . Blood.
2016; ; 128:
:384.–394.
13.
Feng
X,
Zhang
L,
Acharya
C, et al.
Targeting CD38 suppresses Induction and function of T regulatory
cells to mitigate immunosuppression in multiple myeloma .
Clin Cancer Res.
2017; ; 23:
:4290.–4300.
14.
Lokhorst
HM,
Plesner
T,
Laubach
JP, et al.
Targeting CD38 with daratumumab monotherapy in multiple
myeloma . N Engl J Med.
2015; ; 373:
:1207.–1219.
15.
Lonial
S,
Weiss
BM,
Usmani
SZ, et al.
Daratumumab monotherapy in patients with treatment-refractory
multiple myeloma (SIRIUS): an open-label, randomised, phase 2
trial . Lancet.
2016; ; 387:
:1551.–1560.
16.
Clemens
PL,
Yan
X,
Lokhorst
HM, et al.
Pharmacokinetics of daratumumab following intravenous infusion in
relapsed or refractory multiple myeloma after prior proteasome inhibitor and
immunomodulatory drug treatment . Clin
Pharmacokinet.
2017; ; 56:
:915.–924.
17.
Usmani
SZ,
Weiss
BM,
Plesner
T, et al.
Clinical efficacy of daratumumab monotherapy in patients with
heavily pretreated relapsed or refractory multiple myeloma .
Blood.
2016; ; 128:
:37.–44.
18.
Chari
A,
Nahi
H,
Mateos
M-V, et al.
Subcutaneous delivery of daratumumab in patients (pts) with
relapsed or refractory multiple myeloma (RRMM): Pavo, an open-label,
multicenter, dose escalation phase 1b study .
Blood.
2017; ; 130: :838..
19.
Raab
MS,
Chatterjee
M,
Goldschmidt
H, et al.
A phase I/IIa study of the CD38 antibody MOR202 alone and in
combination with pomalidomide or lenalidomide in patients with relapsed or
refractory multiple myeloma .
Blood.
2016; ; 128: :1152..
20.
Richter
JR,
Martin
TG,
Vij
R, et al.
Updated data from a phase II dose finding trial of single agent
isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple
myeloma (RRMM) . J Clin
Oncol.
2016; ; 34: :8005..
21.
Nijhof
IS,
Groen
RW,
Noort
WA, et al.
Preclinical evidence for the therapeutic potential of
CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to
lenalidomide and bortezomib . Clin Cancer
Res.
2015; ; 21:
:2802.–2810.
22.
van der
Veer
MS, de
Weers
M, van
Kessel
B, et al.
The therapeutic human CD38 antibody daratumumab improves the
anti-myeloma effect of newly emerging multi-drug therapies .
Blood Cancer J.
2011; ; 1: :e41..
23.
van der
Veer
MS, de
Weers
M, van
Kessel
B, et al.
Towards effective immunotherapy of myeloma: enhanced elimination
of myeloma cells by combination of lenalidomide with the human CD38
monoclonal antibody daratumumab .
Haematologica.
2011; ; 96:
:284.–290.
24.
Dimopoulos
MA,
Oriol
A,
Nahi
H, et al.
Daratumumab, lenalidomide, and dexamethasone for multiple
myeloma . N Engl J Med.
2016; ; 375:
:1319.–1331.
25.
Martin
T,
Baz
R,
Benson
DM, et al.
A phase 1b study of isatuximab plus lenalidomide and
dexamethasone for relapsed/refractory multiple myeloma .
Blood.
2017; ; 129:
:3294.–3303.
26.
Chari
A,
Suvannasankha
A,
Fay
JW, et al.
Daratumumab plus pomalidomide and dexamethasone in relapsed
and/or refractory multiple myeloma .
Blood.
2017; ; 130:
:974.–981.
27.
Richardson
PG,
Mikhael
J,
Usmani
SZ, et al.
Updated results from a phase Ib study of isatuximab plus
pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple
myeloma (RRMM) . Blood.
2017; ; 130: :1887..
28.
Jakubowiak
AJ,
Chari
A,
Lonial
S, et al.
Daratumumab (DARA) in combination with carfilzomib, lenalidomide,
and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple
myeloma (MMY1001): An open-label, phase 1b study .
J Clin Oncol.
2017; ; 35: :8000..
29.
Palumbo
A,
Chanan-Khan
A,
Weisel
K, et al.
Daratumumab, bortezomib, and dexamethasone for multiple
myeloma . N Engl J Med.
2016; ; 375:
:754.–766.
30.
Nijhof
IS,
Groen
RW,
Lokhorst
HM, et al.
Upregulation of CD38 expression on multiple myeloma cells by
all-trans retinoic acid improves the efficacy of
daratumumab . Leukemia.
2015; ; 29:
:2039.–2049.
31.
Nijhof
IS,
Casneuf
T, van
Velzen
J, et al.
CD38 expression and complement inhibitors affect response and
resistance to daratumumab therapy in myeloma .
Blood.
2016; ; 128:
:959.–970.
32.
Garcia-Guerrero
E,
Gogishvili
T,
Danhof
S, et al.
Panobinostat induces CD38 upregulation and augments the
antimyeloma efficacy of daratumumab .
Blood.
2017; ; 129:
:3386.–3388.
33.
Casneuf
T,
Xu
XS,
Adams
HC, 3rd,
et al.
Effects of daratumumab on natural killer cells and impact on
clinical outcomes in relapsed or refractory multiple
myeloma . Blood Adv.
2017; ; 1:
:2105.–2114.
34.
Wang
Y,
Zhang
Y,
Hughes
T, et al.
Fratricide of NK cells in Daratumumab therapy for multiple
myeloma overcome by ex vivo-expanded autologous NK cells .
Clin Cancer Res.
2018; ; 24:
:4006.–4017.
35.
de Haart
SJ,
Holthof
L,
Noort
WA, et al.
Sepantronium bromide (YM155) improves daratumumab-mediated
cellular lysis of multiple myeloma cells by abrogation of bone marrow
stromal cell-induced resistance .
Haematologica.
2016; ; 101:
:e339.–e342.
36.
van
Bommel
PE,
He
Y,
Schepel
I, et al.
CD20-selective inhibition of CD47-SIRPalpha don’t eat me
signaling with a bispecific antibody-derivative enhances the anticancer
activity of daratumumab, alemtuzumab and obinutuzumab .
Oncoimmunology.
2018; ; 7:
:e1386361..
37.
Rigalou
A,
Ryan
A,
Natoni
A, et al.
Potentiation of anti-myeloma activity of daratumumab with
combination of cyclophosphamide, lenalidomide or bortezomib via a tumor
secretory response that greatly augments macrophage-induced
ADCP . Blood.
2016; ; 128: :2101..
38.
Naicker
S,
Rigalou
A,
McEllistrim
C, et al.
Patient data supports the rationale of low dose cyclophosphamide
to potentiate the anti-myeloma activity of daratumumab through augmentation
of macrophage-induced ADCP .
Blood.
2017; ; 130: :121..
39.
Syn
NL,
Teng
MWL,
Mok
TSK,
Soo
RA. De-novo and
acquired resistance to immune checkpoint targeting .
Lancet Oncol.
2017; ; 18:
:e731.–e741.
40.
Koyama
S,
Akbay
EA,
Li
YY, et al.
Adaptive resistance to therapeutic PD-1 blockade is associated
with upregulation of alternative immune checkpoints .
Nat Comm.
2016; ; 7: :10501..
41.
Chen
L,
Byers
LA,
Ullrich
S, et al.
CD38 as a novel immune checkpoint and a mechanism of resistance
to the blockade of the PD-1/PD-L1 axis . J
Clin Oncol.
2017; ; 35: :79..
42.
Bezman
NA,
Kinder
M,
Jhatakia
AD, et al.
Antitumor activity associated with dual targeting of CD38 and
programmed death-1 (PD-1) pathways in preclinical models .
Cancer Res.
2018;; 78 ( abstract
1727.).